Guidance
Update information
October 2016: Recommendation 1.3.21 and table 1 were updated to remove reference to hip circumference percentile charts. The evidence on choice of antipsychotic medication was reviewed. A new recommendation was added on providing information about olanzapine when choosing antipsychotic medication for children and young people with a first episode of psychosis.
Minor changes since publication
September 2024: We added links to relevant technology appraisal guidance in the sections on first episode psychosis and subsequent acute episodes of psychosis or schizophrenia.
May 2024: We have simplified the guideline by removing recommendations on general principles of care that are covered in other NICE guidelines (for example, the NICE guideline on service user experience in adult mental health). This is a presentational change only, and no changes to practice are intended.
November 2022: Following a surveillance review, we removed the recommendation for research on the clinical and cost effectiveness of omega‑3 fatty acids in the treatment of children and young people considered to be at high risk of developing psychosis. For more information, see appendix A: summary of evidence from surveillance.
December 2021: Following a surveillance review we have updated recommendations 1.3.16 and 1.3.19 and the supplementary information table to say that either glycosylated haemoglobin (HbA1c) or fasting blood glucose may be used to test for diabetes in people taking antipsychotic medication. These recommendations last had an evidence review in 2013, and we updated them without an evidence review in 2021. The recommendations are marked [2013, amended 2021].
ISBN: 978-1-4731-1869-0